These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 15305228

  • 1. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
    Kakizawa H, Itoh Y, Imamura S, Matsumoto T, Ishiwata Y, Ono Y, Yamamoto K, Kato T, Hayakawa N, Oda N, Goto Y, Goto Y, Nagasaka A, Senda T, Itoh M.
    Horm Metab Res; 2004 Jul; 36(7):458-64. PubMed ID: 15305228
    [Abstract] [Full Text] [Related]

  • 2. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
    Kalender B, Oztürk M, Tunçdemir M, Uysal O, Dagistanli FK, Yegenaga I, Erek E.
    Acta Histochem; 2002 Jul; 104(2):123-30. PubMed ID: 12086332
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
    Motawi TK, El-Maraghy SA, Senousy MA.
    J Biochem Mol Toxicol; 2013 Jul; 27(7):378-87. PubMed ID: 23733546
    [Abstract] [Full Text] [Related]

  • 4. Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats.
    Noda M, Fukuda R, Matsuo T, Ohta M, Nagano H, Imura Y, Nishikawa K, Shibouta Y.
    Kidney Int Suppl; 1997 Dec; 63():S136-9. PubMed ID: 9407442
    [Abstract] [Full Text] [Related]

  • 5. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats.
    Nagisa Y, Shintani A, Nakagawa S.
    Diabetologia; 2001 Jul; 44(7):883-8. PubMed ID: 11508274
    [Abstract] [Full Text] [Related]

  • 6. Changes of endothelin in streptozotocin-induced diabetic rats: effects of an angiotensin converting enzyme inhibitor, enalapril maleate.
    Itoh Y, Imamura S, Yamamoto K, Ono Y, Nagata M, Kobayashi T, Kato T, Tomita M, Nakai A, Itoh M, Nagasaka A.
    J Endocrinol; 2002 Oct; 175(1):233-9. PubMed ID: 12379508
    [Abstract] [Full Text] [Related]

  • 7. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
    Erman A, Veksler S, Gafter U, Boner G, Wittenberg C, van Dijk DJ.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
    [Abstract] [Full Text] [Related]

  • 8. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
    Mathew R, Futterweit S, Valderrama E, Tarectecan AA, Bylander JE, Bond JS, Trachtman H.
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
    [Abstract] [Full Text] [Related]

  • 9. Blockade of the renin-angiotensin system improves cerebral microcirculatory perfusion in diabetic hypertensive rats.
    Estato V, Obadia N, Carvalho-Tavares J, Freitas FS, Reis P, Castro-Faria Neto H, Lessa MA, Tibiriçá E.
    Microvasc Res; 2013 May; 87():41-9. PubMed ID: 23466285
    [Abstract] [Full Text] [Related]

  • 10. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A, Tabata M, Hayashi K, Saruta T.
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
    Wada T, Inada Y, Ojima M, Sanada T, Shibouta Y, Nishikawa K.
    Hypertens Res; 1996 Jun; 19(2):75-81. PubMed ID: 10968199
    [Abstract] [Full Text] [Related]

  • 12. Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats.
    Rizzoni D, Porteri E, Bettoni G, Piccoli A, Castellano M, Muiesan ML, Pasini G, Guelfi D, Rosei EA.
    J Cardiovasc Pharmacol; 1998 Nov; 32(5):798-806. PubMed ID: 9821855
    [Abstract] [Full Text] [Related]

  • 13. Superior renoprotective effects of the combination of breviscapine with enalapril and its mechanism in diabetic rats.
    Xu XX, Zhang W, Zhang P, Qi XM, Wu YG, Shen JJ.
    Phytomedicine; 2013 Jul 15; 20(10):820-7. PubMed ID: 23664882
    [Abstract] [Full Text] [Related]

  • 14. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
    Schnack C, Schernthaner G.
    Wien Med Wochenschr; 2001 Jul 15; 151(7-8):165-8. PubMed ID: 11450165
    [Abstract] [Full Text] [Related]

  • 15. Effects of candesartan cilexetil on oxidative state and renal function in 5/6 nephrectomized rats.
    Sugimoto K, Tsuruoka S, Matsushita K, Fujimura A.
    J Hum Hypertens; 1999 Jan 15; 13 Suppl 1():S63-70; discussion S81. PubMed ID: 10076923
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin II receptor antagonist improves age-related endothelial dysfunction.
    Kansui Y, Fujii K, Goto K, Abe I, Iida M.
    J Hypertens; 2002 Mar 15; 20(3):439-46. PubMed ID: 11875311
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes.
    Lee EY, Shim MS, Kim MJ, Hong SY, Shin YG, Chung CH.
    Exp Mol Med; 2004 Feb 29; 36(1):65-70. PubMed ID: 15031673
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
    Hofni A, El-Moselhy MA, Taye A, Khalifa MM.
    Eur J Pharmacol; 2014 Dec 05; 744():173-82. PubMed ID: 25446917
    [Abstract] [Full Text] [Related]

  • 19. Effect of enalapril and losartan on the events that precede diabetic nephropathy in rats.
    Volpini RA, da Silva CG, Costa RS, Coimbra TM.
    Diabetes Metab Res Rev; 2003 Dec 05; 19(1):43-51. PubMed ID: 12592643
    [Abstract] [Full Text] [Related]

  • 20. Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes.
    Zoja C, Cattaneo S, Fiordaliso F, Lionetti V, Zambelli V, Salio M, Corna D, Pagani C, Rottoli D, Bisighini C, Remuzzi G, Benigni A.
    Am J Physiol Renal Physiol; 2011 Nov 05; 301(5):F1114-23. PubMed ID: 21816757
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.